Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and &lt;i&gt;FGFR&lt;/i&gt; Alterations: Final Results From the Phase II NORSE Study
Janssen Research & Development, LLC
Yohann Loriot; Thomas Powles; Victor Moreno; Taek Won Kang; Irfan Cicin; Angela Girvin; Sydney Akapame; Anne O'Hagan; Wei Zhu; Meggan Tammaro; Shibu Thomas; Spyros Triantos; Arlene O Siefker-Radtke